Biocelect is excited to announce its partnership with BioCryst Pharmaceuticals Inc. As a result Biocelect is now the exclusive distributor in Australia for Rapivab (peramivir) a neuraminidase inhibitor for the treatment of acute influenza. An exciting addition to our expanding product range.
Rapivab is the only TGA approved intravenous influenza antiviral available on the current market.
留言